Total Payments
$1.2M
2024 Payments
$136,224
Companies
21
Transactions
1,405
Medicare Patients
534
Medicare Billing
$78,857
Payment Breakdown by Category
Other$774,835 (62.3%)
Consulting$309,646 (24.9%)
Travel$109,968 (8.8%)
Food & Beverage$30,367 (2.4%)
Research$16,759 (1.3%)
Gifts$1,144 (0.1%)
Education$1,026 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $717,251 | 244 | 57.7% |
| Consulting Fee | $309,646 | 88 | 24.9% |
| Travel and Lodging | $109,968 | 519 | 8.8% |
| Honoraria | $57,585 | 17 | 4.6% |
| Food and Beverage | $30,367 | 503 | 2.4% |
| Unspecified | $16,759 | 13 | 1.3% |
| Gift | $1,144 | 8 | 0.1% |
| Education | $1,026 | 13 | 0.1% |
Payments by Type
General
$1.2M
1,392 transactions
Research
$16,759
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $332,985 | 396 | $0 (2024) |
| GENZYME CORPORATION | $155,166 | 207 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $118,922 | 104 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $115,630 | 131 | $0 (2024) |
| Genentech USA, Inc. | $109,833 | 100 | $0 (2024) |
| EMD Serono, Inc. | $108,851 | 147 | $0 (2023) |
| TG Therapeutics, Inc. | $76,471 | 77 | $0 (2024) |
| Horizon Therapeutics plc | $71,638 | 73 | $0 (2023) |
| Celgene Corporation | $57,228 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $34,116 | 49 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $136,224 | 159 | TG Therapeutics, Inc. ($39,250) |
| 2023 | $192,484 | 177 | Alexion Pharmaceuticals, Inc. ($37,869) |
| 2022 | $188,645 | 197 | E.R. Squibb & Sons, L.L.C. ($60,386) |
| 2021 | $90,648 | 80 | Biogen, Inc. ($22,602) |
| 2020 | $74,585 | 75 | Biogen, Inc. ($25,497) |
| 2019 | $227,340 | 270 | Biogen, Inc. ($99,679) |
| 2018 | $151,004 | 190 | Biogen, Inc. ($72,853) |
| 2017 | $182,814 | 257 | GENZYME CORPORATION ($78,578) |
All Payment Transactions
1,405 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $709.45 | Research |
| Study: Exposure-Response Analyses of Ocrelizumab in Patients With Relapsing Multiple Sclerosis in OPERA I and II Over 10 Years • Category: Immunology | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $201.76 | General |
| Category: Neuroscience | ||||||
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $51.57 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,690.00 | General |
| Category: Neurology | ||||||
| 12/06/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $1,552.50 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $1,127.35 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,614.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Travel and Lodging | Cash or cash equivalent | $37.52 | General |
| Category: Immunology | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,759.00 | General |
| Category: Neuroscience | ||||||
| 11/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $930.00 | General |
| Category: Immunology | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $40.70 | General |
| Category: Neuroscience | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $37.00 | General |
| Category: Neuroscience | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $30.82 | General |
| Category: Neuroscience | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.81 | General |
| Category: Neuroscience | ||||||
| 11/01/2024 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,690.00 | General |
| Category: Neurology | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $500.91 | General |
| Category: Neuroscience | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $435.07 | General |
| Category: Neuroscience | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $253.65 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $8,750 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $6,236 | 10 |
| AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $1,064 | 1 |
| Exposure-Response Analyses of Ocrelizumab in Patients With Relapsing Multiple Sclerosis in OPERA I and II Over 10 Years | F. Hoffmann-La Roche AG | $709.45 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 129 | 190 | $62,060 | $19,664 |
| 2022 | 3 | 132 | 209 | $67,345 | $21,018 |
| 2021 | 5 | 161 | 234 | $74,979 | $23,585 |
| 2020 | 4 | 112 | 160 | $52,604 | $14,590 |
Total Patients
534
Total Services
793
Medicare Billing
$78,857
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 127 | $39,624 | $12,904 | 32.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 31 | $13,578 | $4,234 | 31.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 13 | 19 | $5,985 | $1,655 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 13 | $2,873 | $870.02 | 30.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 84 | 150 | $46,800 | $14,610 | 31.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 24 | $10,080 | $3,401 | 33.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 26 | 35 | $10,465 | $3,007 | 28.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 76 | 125 | $39,000 | $12,096 | 31.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 27 | 45 | $13,455 | $4,525 | 33.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 29 | 32 | $13,440 | $4,181 | 31.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $7,735 | $2,248 | 29.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 16 | 19 | $1,349 | $534.98 | 39.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 59 | 92 | $27,324 | $7,331 | 26.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 20 | 33 | $9,276 | $3,153 | 34.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 21 | 23 | $9,200 | $2,365 | 25.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 12 | 12 | $6,804 | $1,742 | 25.6% |
About Pavle Repovic, MD, PHD
Pavle Repovic, MD, PHD is a Neurology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1649437211.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Pavle Repovic, MD, PHD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $136,224 received in 2024. These payments were reported across 1,405 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($717,251).
As a Medicare-enrolled provider, Repovic has provided services to 534 Medicare beneficiaries, totaling 793 services with total Medicare billing of $78,857. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Seattle, WA
- Active Since 05/20/2008
- Last Updated 06/25/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1649437211
Products in Payments
- ZEPOSIA (Drug) $127,261
- LEMTRADA (Drug) $90,233
- TECFIDERA (Drug) $88,689
- VUMERITY (Drug) $73,199
- UPLIZNA (Drug) $71,638
- TYSABRI (Biological) $68,659
- BRIUMVI (Drug) $66,964
- OCREVUS (Biological) $60,654
- AUBAGIO (Drug) $59,834
- Rebif (Biological) $38,122
- SOLIRIS (Biological) $29,572
- ULTOMIRIS (Biological) $27,732
- Enspryng (Biological) $25,535
- Mavenclad (Biological) $25,395
- Ocrevus (Biological) $23,282
- Non-Covered Product (Drug) $22,541
- Ozanimod (Drug) $17,476
- Soliris (Drug) $14,910
- Mavenclad (Drug) $11,523
- COPAXONE (Drug) $10,514
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Seattle
Nathaniel Watson, Md, MD
Neurology — Payments: $352,101
Neurology $352,101
Mariko Kita, Md, MD
Neurology — Payments: $243,050
Neurology $243,050
Kyra Becker
Neurology — Payments: $239,174
Neurology $239,174
Christyn Edmundson, Md, MD
Neurology — Payments: $226,530
Neurology $226,530
Pravin Khemani, Md, MD
Neurology — Payments: $199,884
Neurology $199,884
Yince Loh, M.d, M.D
Neurology — Payments: $177,017
Neurology $177,017